PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33075166-3	2021	Here, we aimed to evaluate the characteristics, prognosis, and treatment efficacy of an FLT3 inhibitor (regorafenib) in patients with mCRC with FLT3 amplifications.	regorafenib	104-115	fms related receptor tyrosine kinase 3	Homo sapiens	88-92	
33075166-3	2021	Here, we aimed to evaluate the characteristics, prognosis, and treatment efficacy of an FLT3 inhibitor (regorafenib) in patients with mCRC with FLT3 amplifications.	regorafenib	104-115	fms related receptor tyrosine kinase 3	Homo sapiens	144-148	
27045179-1	2016	Regorafenib {systematic name: 4-[4-({[4-chloro-3-(trifluoromethy)phenyl]carbamoyl}amino)-3-fluorophenoxy]-1-methylpyridine-2-carboxamide}, C21H15ClF4N4O3, is a potent anticancer and anti-angiogenic agent that possesses various activities on the VEGFR, PDGFR, raf and/or flt-3 kinase signaling molecules.	regorafenib	0-11	fms related receptor tyrosine kinase 3	Homo sapiens	270-275